RPL22P8

Across TCGA pan-cancer cohorts, RPL22P8 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of RPL22P8’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RPL22P8 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL22P8 is over-expressed in tumor, although a few such as BRCA and CHOL show the opposite, repressed pattern.

BRCA, PRAD, and LIHC are the cancer types where RPL22P8 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL22P8 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	II,III,IV	−0.069	.001	6	view →
PRAD	All	All	+0.121	.004	2	view →
LIHC	Female	II,III,IV	+0.071	.041	2	view →
CHOL	Female	All	−0.203	<.001	1	view →
KIRC	Female	IV	+0.148	.010	1	view →
THCA	Male	All	−0.121	.044	1	view →
LIHC	Male	III,IV	−0.113	.004	1	view →
LUAD	All	All	+0.110	.039	1	view →
LUSC	Male	II,III,IV	+0.106	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 8 lineages.

RPL22P8–BRCA

Open the BRCA breakdown →